Prognostic value of ERCC1, RRM1, and TS proteins in patients with resected non-small cell lung cancer.
OBJECTIVE
Recent clinical trials showed that expression of excision repair cross-complementation group 1 (ERCC1), ribonucleotide reductase M1 (RRM1), and thymidylate synthase (TS) proteins was able to predict the effects of non-small cell lung cancer (NSCLC) to chemotherapy. However, it remains unknown whether the adjuvant chemotherapy based on expression of the three proteins has survival significance in Chinese NSCLC patients.


METHODS
We investigated 128 Chinese patients receiving chemotherapy after tumor resection for expression of these proteins using immunohistochemistry. Based on protein expression, patients were assigned to two groups for different adjuvant chemotherapy regimes. The disease-free survival (DFS) data were collected and analyzed using Kaplan-Meier curves and Cox models.


RESULTS
We found that DFS of these patients with carboplatin and a third-generation agent (gemcitabine or pemetrexed) stratified by protein expression showed no statistical difference between individual treatment versus non-individuation treatment analyzed using Kaplan-Meier method (P = 0.143, median 23.9 vs. 30.8 months). Furthermore, the multivariate analysis showed that histology and tumor stages were independent predictors for DFS in these patients.


CONCLUSIONS
The results suggest that chemotherapy based on ERCC1, RRM1, and TS expression did not have significant impact on DFS of patients with resection of NSCLC.
Department of Pharmacy, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Yu-Wen
YW
He
Mei-Ling
ML
Zhao
Xin-Yun
XY
Yang
Jun
J
Zeng
Qiu-Hua
QH
Deng
Jian-Xing
JX
He
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D016190:Carboplatin / Q000008:administration & dosage / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002681:China; D004268:DNA-Binding Proteins / Q000096:biosynthesis*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D004334:Drug Administration Schedule; D004720:Endonucleases / Q000096:biosynthesis*; D005971:Glutamates / Q000008:administration & dosage / Q000627:therapeutic use; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000601:surgery; D008297:Male; D000068437:Pemetrexed; D057285:Precision Medicine; D011237:Predictive Value of Tests; D011446:Prospective Studies; D012262:Ribonucleoside Diphosphate Reductase; D013940:Thymidylate Synthase / Q000096:biosynthesis*; D025521:Tumor Suppressor Proteins / Q000096:biosynthesis*; D000093542:Gemcitabine
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D005971:Glutamates; D025521:Tumor Suppressor Proteins; D000068437:Pemetrexed; D003841:Deoxycytidine; D006147:Guanine; D016190:Carboplatin; C475286:RRM1 protein, human; D012262:Ribonucleoside Diphosphate Reductase; D013940:Thymidylate Synthase; C071447:ERCC1 protein, human; D004720:Endonucleases; D000093542:Gemcitabine